Nothing Special   »   [go: up one dir, main page]
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2013 1
2017 1
2019 1
2020 2
2021 2
2022 3
2023 3
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells.
Dost AFM, Moye AL, Vedaie M, Tran LM, Fung E, Heinze D, Villacorta-Martin C, Huang J, Hekman R, Kwan JH, Blum BC, Louie SM, Rowbotham SP, Sainz de Aja J, Piper ME, Bhetariya PJ, Bronson RT, Emili A, Mostoslavsky G, Fishbein GA, Wallace WD, Krysan K, Dubinett SM, Yanagawa J, Kotton DN, Kim CF. Dost AFM, et al. Cell Stem Cell. 2020 Oct 1;27(4):663-678.e8. doi: 10.1016/j.stem.2020.07.022. Epub 2020 Sep 4. Cell Stem Cell. 2020. PMID: 32891189 Free PMC article.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2024 May;14(4_suppl):690S-714S. doi: 10.1177/21925682241245615. Global Spine J. 2024. PMID: 38726630 Free PMC article. No abstract available.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
The power of mentorship.
Lewis CP, Johnson BH, Donnell C, Phillips T, Jackson D, Backus M, Payne A, Greenwell RW, Wentz A. Lewis CP, et al. Nurs Manage. 2019 Jul;50(7):38-44. doi: 10.1097/01.NUMA.0000558524.37370.ce. Nurs Manage. 2019. PMID: 31246653
Surgical data science - from concepts toward clinical translation.
Maier-Hein L, Eisenmann M, Sarikaya D, März K, Collins T, Malpani A, Fallert J, Feussner H, Giannarou S, Mascagni P, Nakawala H, Park A, Pugh C, Stoyanov D, Vedula SS, Cleary K, Fichtinger G, Forestier G, Gibaud B, Grantcharov T, Hashizume M, Heckmann-Nötzel D, Kenngott HG, Kikinis R, Mündermann L, Navab N, Onogur S, Roß T, Sznitman R, Taylor RH, Tizabi MD, Wagner M, Hager GD, Neumuth T, Padoy N, Collins J, Gockel I, Goedeke J, Hashimoto DA, Joyeux L, Lam K, Leff DR, Madani A, Marcus HJ, Meireles O, Seitel A, Teber D, Ückert F, Müller-Stich BP, Jannin P, Speidel S. Maier-Hein L, et al. Med Image Anal. 2022 Feb;76:102306. doi: 10.1016/j.media.2021.102306. Epub 2021 Nov 18. Med Image Anal. 2022. PMID: 34879287 Free PMC article. Review.
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Nascimento CND, Caron B, Kitsou V, Bamias G, García MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, Karmiris K, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, Magro F, Carla F, Fiorino G. Allocca M, et al. United European Gastroenterol J. 2024 Jun;12(5):543-551. doi: 10.1002/ueg2.12492. Epub 2024 Feb 28. United European Gastroenterol J. 2024. PMID: 38419274 Free PMC article.
Secondary outcomes were clinical remission, normalization of C-reactive protein, endoscopic remission, treatment withdrawal, and adverse events. ...
Secondary outcomes were clinical remission, normalization of C-reactive protein, endoscopic remission, treatment withdrawal, and adve …
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.
Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, Sanchez-Rivera FJ, Pessina P, Kim JY, Simoneau A, Paschini M, Beytagh MC, Stanclift CR, Schenone M, Mani DR, Li C, Oh A, Li F, Hu H, Karatza A, Bronson RT, Shaw AT, Hata AN, Wong KK, Zou L, Carr SA, Jacks T, Kim CF. Gupta M, et al. Cancer Res. 2020 Sep 15;80(18):3841-3854. doi: 10.1158/0008-5472.CAN-20-1744. Epub 2020 Jul 20. Cancer Res. 2020. PMID: 32690724 Free PMC article.
A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.
Steeghs N, Pruis M, van Herpen C, Lu V, Redman J, Zhou X. Steeghs N, et al. Invest New Drugs. 2023 Feb;41(1):53-59. doi: 10.1007/s10637-022-01318-3. Epub 2022 Nov 21. Invest New Drugs. 2023. PMID: 36409435 Free PMC article. Clinical Trial.
Median T(max) was achieved approximately 2 h post-dose of TAK-931 80 mg for both tablet and PIC. Geometric mean C(max), AUC exposures, and T(1/2z) of TAK-931 were similar for both formulations. Geometric mean C(max), AUC(last), and AUC(inf) ratios were 0.936 (90% co …
Median T(max) was achieved approximately 2 h post-dose of TAK-931 80 mg for both tablet and PIC. Geometric mean C(max), AUC exposures …
16 results